Please use this identifier to cite or link to this item: https://apo.ansto.gov.au/dspace/handle/10238/3003
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDenoyer, D-
dc.contributor.authorPotdevin, T-
dc.contributor.authorRoselt, P-
dc.contributor.authorNeels, OC-
dc.contributor.authorKirby, L-
dc.contributor.authorGreguric, I-
dc.contributor.authorKatsifis, A-
dc.contributor.authorDorow, DS-
dc.contributor.authorHicks, RJ-
dc.date.accessioned2011-02-09T05:56:42Z-
dc.date.available2011-02-09T05:56:42Z-
dc.date.issued2011-01-01-
dc.identifier.citationDenoyer, D., Potdevin, T., Roselt, P., Neels, O. C., Kirby, L., Greguric, I., Katsifis, A., Dorow, D. S., & Hicks, R. J. (2011). Improved detection of regional melanoma metastasis using 18F-6-Fluoro-N-[2-(Diethylamino)Ethyl] Pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. Journal of Nuclear Medicine, 52(1), 115-122. doi:10.2967/jnumed.110.078154en_AU
dc.identifier.govdoc3196-
dc.identifier.issn0161-5505-
dc.identifier.urihttp://dx.doi.org/10.2967/jnumed.110.078154en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/3003-
dc.description.abstractThe efficacy of differing routes of administration of 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide (18F-MEL050), a new benzamide-based PET radiotracer for imaging regional lymph node metastasis in melanoma, was assessed. Methods: B16-Black/6 metastatic melanoma cells harboring an mCherry transgene were implanted into the left-upper-foot surface of 49 C57 Black/6 mice as a model of popliteal lymph node (PLN) metastasis. Ultrasound scanning of the left PLN was performed at baseline and in combination with 18F-MEL050 PET on days 5, 9, and 14. Mice were divided into 2 groups to compare the results of tracer administration either subcutaneously at the tumor site (local) or in the lateral tail vein (systemic). After PET on each imaging day, 5 mice per group—including any with evidence of metastasis—were sacrificed for ex vivo validation studies including assessment of retained radioactivity and presence of the mCherry transgene as a surrogate of nodal tumor burden. Results: Nine mice were judged as positive for PLN metastasis by ultrasound at day 5, and 8 PLNs were positive on 18F-MEL050 PET, 3 after systemic and 5 after local administration. Ex vivo analysis showed that ultrasound correctly identified 90% of positive PLNs, with 1 false-positive. 18F-MEL050 PET correctly identified 60% of positive PLNs after systemic administration and 100% after local administration with no false-positive results by either route. The average node-to-background ratio for positive PLNs was 6.8 in the systemic-administration group and correlated with disease burden. In the local-administration group, the mean uptake ratio was 48, without clear relation to metastatic burden. Additional sites of metastatic disease were also correctly identified by 18F-MEL050 PET. Conclusion: In addition to its potential for systemic staging, perilesional administration of 18F-MEL050 may allow sensitive and specific, noninvasive identification of regional lymph node metastasis in pigmented malignant melanomas. © 2011, Society of Nuclear Medicineen_AU
dc.language.isoenen_AU
dc.publisherSociety of Nuclear Medicineen_AU
dc.subjectNeoplasmsen_AU
dc.subjectMiceen_AU
dc.subjectPositron computed tomographyen_AU
dc.subjectTracer techniquesen_AU
dc.subjectMelaninen_AU
dc.subjectRadioactivityen_AU
dc.titleImproved detection of regional melanoma metastasis using 18F-6-Fluoro-N-[2-(Diethylamino)Ethyl] Pyridine-3-Carboxamide, a Melanin-specific PET probe, by perilesional administration.en_AU
dc.typeJournal Articleen_AU
dc.date.statistics2011-01-01-
Appears in Collections:Journal Articles

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.